Vivus presents promising new TA-1790 data in erectile dysfunction

Vivus has released positive data on TA-1790, its investigational PDE -5 inhibitor for treatment of erectile dysfunction.

Results from the pharmacokinetic (PK) study show that TA-1790 was rapidly absorbed after ingestion with median peak plasma levels achieved at 40 minutes (range 20-90 min). For an on-demand erectile dysfunction (ED) medication, this rate of absorption compares favorably to the median peak plasma level of 60 minutes (range 30-120 min) for Pfizer's Viagra.

Importantly, 89% (24/27) of patients on 50mg TA - 1790 achieved greater than 60% penile rigidity in the 20-40 minute time frame as compared to only 46% (12/26) of patients on 50mg of sildenafil. Based on these results, Vivus is proceeding with patient enrollment in an at-home study of TA 1790.